FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company will present data on a novel nucleotide analog, GS 9219, which has shown evidence of anti-cancer activity in preclinical studies, at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), which will take place in Los Angeles on April 14-18, 2007.
